Results 11 to 20 of about 26,870 (208)

Tralokinumab Versus Dupilumab for the Treatment of Atopic Dermatitis with Moderate-to-Severe Hand Involvement: A Matching-Adjusted Indirect Comparison [PDF]

Dermatology and Therapy
Introduction Both tralokinumab and dupilumab have shown efficacy in atopic dermatitis (AD) with moderate-to-severe hand involvement in double-blind phase 3 trials.
April Armstrong, Leon Kircik, Andrei Metelitsa, Richard B. Warren, Adrian Rodriguez, Sebastian Volc, Naiem Issa, Raj Chovatiya, Rie von Eyben, Teodora Festini, Pierre Johansen, Benjamin Ehst   +11 more
doaj   +2 more sources

A Matching-Adjusted Indirect Comparison of Guselkumab and Secukinumab in Patients with Psoriatic Arthritis Over 52 Weeks [PDF]

Rheumatology and Therapy
Introduction Studies evaluating the long-term comparative efficacy between biologic therapies for psoriatic arthritis (PsA) are scarce. Two biologic therapies, guselkumab and secukinumab, were evaluated up to 52 weeks in a mixed patient population ...
Suzy van Sanden, Agata Schubert, Barkha P. Patel, Miriam Zimmermann, Fareen Hassan   +4 more
doaj   +2 more sources

Matching-adjusted indirect comparison of fruquintinib versus ramucirumab in advanced gastric or gastroesophageal junction adenocarcinoma [PDF]

Journal of Comparative Effectiveness Research
Aim: Fruquintinib (Fruq), a selective VEGFR 1/2/3 inhibitor, showed a significant progression-free survival (PFS) benefit in the Phase III FRUTIGA trial for advanced gastric/gastroesophageal junction (G/GEJ) adenocarcinoma.
Nan An, Jiaying Chen, Jibin Li, Lin Shen, Weijian Guo, Tianshu Liu, Jin Li, Shukui Qin, Yuxian Bai, Zhendong Chen, Jufeng Wang, Yueyin Pan, Ruihua Xu, Feng Wang   +13 more
doaj   +2 more sources

Matching-Adjusted Indirect Comparison of Risankizumab Versus Deucravacitinib in Patients with Moderate-to-Severe Plaque Psoriasis [PDF]

Dermatology and Therapy
Introduction Despite advancements in the treatment of psoriasis (PsO), there are few head-to-head studies assessing comparative effectiveness of the newest therapies approved to treat PsO.
April W. Armstrong, Ahmed M. Soliman, Paolo Gisondi, Siran Fang, Manish Patel, Bruce Strober   +5 more
doaj   +2 more sources

Matching-Adjusted Indirect Comparison of Arterial FOLFOX and Atezolizumab-Bevacizumab in Unresectable Hepatocellular Carcinoma [PDF]

Liver Cancer
Introduction: A previous phase 3 FOHAIC-1 study demonstrated that hepatic arterial infusion chemotherapy (HAIC) of FOLFOX regimen displayed favorable outcomes in advanced hepatocellular carcinoma (HCC) patients, including those with high-risk ...
Yi-Min Zhang, Xin-Tong Wu, Jun-Zhe Yi, Jie Xu, Yu-Nan Zhang, Ning Lyu, Ming Zhao   +6 more
doaj   +2 more sources

Matching-adjusted indirect comparison between garadacimab and lanadelumab for the long-term prophylactic treatment of patients with hereditary angioedema [PDF]

Journal of Comparative Effectiveness Research
Aim: This study aimed to estimate the relative efficacy between garadacimab 200 mg once monthly (200 QM) and two dosing regimens of lanadelumab (300 mg once every 2 weeks [300 Q2W] and 300 mg once every 4 weeks [300 Q4W]) in adolescent/adult patients ...
Sarah Walsh, Anja Haltner, Meaghan Bartlett, John Sears, Yinglei Li, Maebh Kelly, Simona Gavata-Steiger, Chiara Nenci, Iris Jacobs, Ingo Pragst, Neelanjana Ray, Imtiaz A Samjoo   +11 more
doaj   +2 more sources

Matching-adjusted indirect comparison of kidney function in patients with immunoglobulin A nephropathy treated with nefecon or sparsentan [PDF]

Journal of Comparative Effectiveness Research
Aim: We compared the effects of nefecon, an oral targeted-release budesonide formulation, and sparsentan, an oral, dual endothelin-angiotensin receptor antagonist, on estimated glomerular filtration rate (eGFR) in patients with immunoglobulin A ...
Christopher Ngai, Mit Patel, Agnieszka Kopiec, Shuai Fu, Noemi Hummel   +4 more
doaj   +2 more sources

Matching-adjusted indirect comparison of tislelizumab plus lenvatinib versus sintilimab plus bevacizumab biosimilar as first-line treatment for unresectable hepatocellular carcinoma [PDF]

Frontiers in Immunology
BackgroundProgrammed cell death-1/programmed cell death-ligand 1 (PD-[L]1) inhibitors plus bevacizumab (or biosimilars) or tyrosine kinase inhibitors (TKIs) have been widely used for the first-line treatment of patients with unresectable hepatocellular ...
Kunyuan Wang, Kunyuan Wang, Chang Liu, Xiaoling Song, Na Zhao, Xin Zheng   +5 more
doaj   +2 more sources

Matching-Adjusted Indirect Comparison of the Efficacy of Delgocitinib Cream and Dupilumab in the Treatment of Moderate to Severe Atopic Hand Eczema [PDF]

Dermatology and Therapy
Introduction A matching-adjusted indirect comparison (MAIC) was performed comparing the efficacy of delgocitinib and dupilumab in patients with atopic hand eczema (AHE), one aetiological subtype of chronic hand eczema (CHE).
David Cohen, Anthony Bewley, Andreas Wollenberg, H. Chih-ho Hong, April Armstrong, Emilie Jonsen, Douglas Maslin, Henrik Thoning, Rie von Eyben, Raj Chovatiya   +9 more
doaj   +2 more sources

Letter to the Editor Regarding “Anchored Matching-Adjusted Indirect Comparison of the Long-Term Maintenance of Efficacy of Tralokinumab and Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis” [PDF]

Dermatology and Therapy
Kim Rand, Kurt Gebauer, Yousef Binamer, Yung-Tsu Cho, Manny Papadimitropoulos, Chao Yang, Helena Agell, Bülent Akmaz, Lucia Seminario-Vidal   +8 more
doaj   +2 more sources